🇺🇸 FDA
Pipeline program

Olaparib, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione, Cisplatino Sandoz 1 mg/ml – Concentrato per soluzione per infusione, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, CARBOPLATINO TEVA 10 mg/ml

IRST162.14

Phase 2 small_molecule active

Quick answer

Olaparib, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione, Cisplatino Sandoz 1 mg/ml – Concentrato per soluzione per infusione, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, CARBOPLATINO TEVA 10 mg/ml for Extensive-Stage Small-Cell Lung Cancer (ES SCLC) is a Phase 2 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).

Program details

Company
Istituto Gentili S.r.l.
Indication
Extensive-Stage Small-Cell Lung Cancer (ES SCLC)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials